Initiates Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)

Research analysts at started coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMDGet Rating) in a research note issued on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Trading Up 4.6 %

Shares of GLMD stock opened at $0.52 on Friday. Galmed Pharmaceuticals has a 1-year low of $0.29 and a 1-year high of $1.84. The company has a current ratio of 4.07, a quick ratio of 4.07 and a debt-to-equity ratio of 0.01. The stock has a 50-day moving average of $0.65 and a 200-day moving average of $0.47. The stock has a market cap of $13.05 million, a price-to-earnings ratio of -0.58 and a beta of 1.11.

Institutional Trading of Galmed Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of GLMD. Millennium Management LLC boosted its stake in Galmed Pharmaceuticals by 372.3% during the second quarter. Millennium Management LLC now owns 50,748 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 40,003 shares during the period. Cambridge Investment Research Advisors Inc. bought a new stake in Galmed Pharmaceuticals during the first quarter worth about $42,000. Finally, Raymond James Financial Services Advisors Inc. lifted its stake in Galmed Pharmaceuticals by 158.9% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 63,310 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 38,856 shares during the last quarter. 10.30% of the stock is owned by hedge funds and other institutional investors.

About Galmed Pharmaceuticals

(Get Rating)

Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.

Read More

Analyst Recommendations for Galmed Pharmaceuticals (NASDAQ:GLMD)

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with's FREE daily email newsletter.